Table 1.
Results of quantitative real time kinetoplast DNA (qRT-kDNA) PCR targeting Leishmania DNA extracted from samples collected with microbiopsy (MB) device types 1 and 2 (MB1, MB2) and finger pricks (FP) from 10 hospitalized leishmaniasis patients during the pilot study.
| Noa | Parasite concentrations (per ml) |
Patient information | |||||
|---|---|---|---|---|---|---|---|
| MB type | MB Location |
FP | |||||
| Arm | Back | Nape of Neck | Face | ||||
| 1 | MB1 | 0 | 10 (0.1) | – | – | 278 | Pre-treated VL+ |
| MB2 | 60 | 30 (34·5) | – | – | |||
| 2 | MB1 | 80 | – | 10 | – | 92,714 | Pre-treated VL+ |
| MB2 | 3,920 | – | 2,850 | – | |||
| 3 | MB1 | 10 | – | 10 | – | 2,810 | Pre-treated VL+ |
| MB2 | 2,710 | – | 80 | – | |||
| 4 | MB1 | 10 | – | – | – | 279 | Pre-treated VL+ |
| MB2 | 70 | – | – | – | |||
| 5 | MB1 | 20 | – | 0 | 0 | 405 | Pre-treated VL+ |
| MB2 | 20 | – | 260 | 930 | |||
| 7 | MB1 | – | – | – | 10 | 829 | Pre-treated VL+ |
| MB2 | 20 | – | – | 340 | |||
| 6 | MB1 | 20 | – | – | 0 | 18 | VL+ 6th day of treatment with Sodium stibogluconate |
| MB2 | 70 | – | – | 10 | |||
| 8 | MB1b | 20,130 | – | – | – | >106 | Co-infection VL+ HIV, hard skin nodules, signs of PKDL |
| MB2 | 1,080 | – | – | – | |||
| 9 | MB1c | – | – | – | 1,160 | 7,156 | PKDL Grade 1 |
| MB2 | – | – | – | 650 | |||
| 10 | MB1 | – | 60 | – | – | 250 | Diffuse CL, 3 years treatment |
| MB2 | – | 10 | – | – | |||
VL, visceral leishmaniasis; HIV, human immunodeficiency virus; CL, cutaneous leishmaniasis.
a
Patients 1 to 8 were diagnosed serologically using rK39 rapid tests followed by splenic punctures.
b
MB1 device was applied to a papular post-kala azar dermal leishmaniasis (PKDL) lesion (scattered lesions were observed only on the face restricted to areas around the nose and mouth).
c
MB1 device was applied directly on the surface of a hard skin nodule in the forearm.